Peginterferon alfa-2b (PEG2b) — Competitive Intelligence Brief

Peginterferon alfa-2b (PEG2b) (Peginterferon alfa-2b (PEG2b)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interferon. Area: Virology.

phase 3 Interferon Interferon-alpha receptor Virology Small molecule

Target snapshot

Peginterferon alfa-2b (PEG2b) (Peginterferon alfa-2b (PEG2b)) — Merck Sharp & Dohme LLC. Peginterferon alfa-2b (PEG2b) is a pegylated form of interferon alfa-2b, which works by stimulating the body's immune system to fight viral infections.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Peginterferon alfa-2b (PEG2b) TARGET	Peginterferon alfa-2b (PEG2b)	Merck Sharp & Dohme LLC	phase 3	Interferon	Interferon-alpha receptor
Pegylated interferon and ribavirin	Pegylated interferon and ribavirin	Pacific Health Foundation	marketed	Antiviral combination therapy	Interferon-alpha receptor; Hepatitis C virus RNA-dependent RNA polymerase
Pegylated Interferon alpha-2a	Pegylated Interferon alpha-2a	ANRS, Emerging Infectious Diseases	marketed	Interferon alpha	Interferon-alpha receptor (IFNAR)
Peginterferon alfa-2a with Ribavirin	Peginterferon alfa-2a with Ribavirin	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	marketed	Interferon alpha with nucleoside analog	Interferon-alpha receptor (IFNAR); HCV RNA-dependent RNA polymerase
Peginterferon alfa-2a 40KD and Ribavirin	Peginterferon alfa-2a 40KD and Ribavirin	NORDynamIC Study Group	marketed	Interferon alpha with nucleoside analog	Interferon-alpha receptor (IFNAR); viral RNA-dependent RNA polymerase
Pegylated Interferon Alfa 2a	Pegylated Interferon Alfa 2a	Vertex Pharmaceuticals Incorporated	marketed	Interferon alpha	Interferon-alpha receptor (IFNAR)
Peg-IFN + WB RBV for 24 weeks	Peg-IFN + WB RBV for 24 weeks	National Taiwan University Hospital	marketed	Immunomodulator + nucleoside analog antiviral combination	Interferon-alpha receptor (IFNAR); HCV RNA-dependent RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interferon class)

1. EMD Serono · 3 drugs in this class
2. Cinnagen · 2 drugs in this class
3. Tanabe Pharma Corporation · 2 drugs in this class
4. Biogen · 1 drug in this class
5. Celgene · 1 drug in this class
6. EMD Serono Research & Development Institute, Inc. · 1 drug in this class
7. Case Comprehensive Cancer Center · 1 drug in this class
8. Hoffmann-La Roche · 1 drug in this class
9. Human Genome Sciences Inc. · 1 drug in this class
10. Bayer · 1 drug in this class